NovoCure Limited
NVCRNASDAQHealthcare● Active
$17.40
+$0.24(+1.39%)
Market Cap$2.0B
P/E Ratio—
52W High$19.25
52W Low$9.82
NovoCure Limited (NVCR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NVCR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.66B | $0.61B | $0.51B | $0.54B | $0.54B |
| Cost of Revenue | $0.17B | $0.14B | $0.13B | $0.11B | $0.11B |
| Gross Profit | $0.49B | $0.47B | $0.38B | $0.42B | $0.42B |
| Gross Margin %(computed) | 74.54% | 77.33% | 74.81% | 78.64% | 78.53% |
| Operating Expenses | |||||
| R&D Expenses | $0.22B | $0.21B | $0.22B | $0.21B | $0.20B |
| G&A Expenses | $0.18B | $0.19B | $0.16B | $0.13B | $0.13B |
| Total Operating Expenses | $0.64B | $0.64B | $0.61B | $0.51B | $0.46B |
| Operating Income | ($0.15B) | ($0.17B) | ($0.23B) | ($0.09B) | ($0.04B) |
| Operating Margin %(computed) | -23.47% | -28.17% | -45.72% | -16.64% | -8.29% |
| Interest Income | $0.02B | $0.05B | $0.05B | $0.02B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.00B | $0.01B | $0.01B |
| Income Before Tax | ($0.14B) | ($0.13B) | ($0.19B) | ($0.08B) | ($0.05B) |
| Income Tax Expense | ($0.00B) | $0.04B | $0.02B | $0.01B | $0.01B |
| Net Income | ($0.14B) | ($0.17B) | ($0.21B) | ($0.09B) | ($0.06B) |
| Net Margin %(computed) | -20.79% | -27.86% | -40.65% | -17.20% | -10.91% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
| Wtd Avg Shares | 0.11B | 0.11B | 0.11B | 0.10B | 0.10B |
| EBITDA | ($0.12B) | ($0.11B) | ($0.18B) | ($0.07B) | ($0.04B) |
| EBITDA Margin %(computed) | -18.17% | -18.11% | -34.84% | -12.62% | -7.17% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more NovoCure Limited data
About NovoCure Limited (NVCR) Income Statement
NovoCure Limited (NVCR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NVCR reported revenue of $0.66B, gross profit of $0.49B (gross margin 74.54%), and net income of ($0.14B) — a net profit margin of -20.79%.
Frequently asked questions
NVCR · 4 questionsNovoCure Limited (NVCR) reported revenue of $0.66B for 2025, up 8.3% year-over-year.
NVCR revenueNVCR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08